SCHEMBL6946528

SCHEMBL6946528

CC1C(=O)CCN2c3ccccc3CCC12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 5/20 0.52
HTR2C P28335 3/20 0.42
HTR2B P41595 3/20 0.42
GAA P10253 4/20 0.41
GFER P55789 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16307948 0.71 HTR2C (0.49) SRD5A1HTR2CHTR2BMEN1KMT2A
SCHEMBL7128885 0.70 KMT2A (0.43) SRD5A1HTR2CGAAGFERLMNA
SCHEMBL23513476 0.70 GAA (0.44) SRD5A1HTR2CHTR2BGAAGFER
SCHEMBL6945075 0.69 HTR2C (0.55) SRD5A1HTR2CHTR2BGAAGFER
SCHEMBL6945937 0.69 SRD5A1 (1.00) SRD5A1CHRM2CHRM4CHRM1CHRM3
SCHEMBL6945939 0.69 SRD5A1 (1.00) SRD5A1CHRM2CHRM4CHRM1CHRM3
SCHEMBL6943973 0.69 SRD5A1 (1.00) SRD5A1CHRM2CHRM4CHRM1CHRM3
SCHEMBL7052742 0.69 SRD5A1 (1.00) SRD5A1CHRM2CHRM4CHRM1CHRM3
SCHEMBL3723794 0.68 OPRM1 (0.65) HTR2CHTR2BGAAGFERLMNA
SCHEMBL24762571 0.66 OPRM1 (0.51) HTR2CHTR2BGAAGFERLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0999747-B1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-23 EP claimed
US-6514912-B1 Use of benzo[C]quinolizine derivatives as plant growth regulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-04 US claimed
US-20010047098-A1 Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-29 US claimed
US-20010044542-A1 Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-22 US claimed
EP-0880520-A1 BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1998-12-02 EP claimed
WO-1997029107-A1 BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5α-REDUCTASES INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1997-08-14 WO claimed
US-6555549-B2 Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-04-29 US disclosed
EP-0999747-B1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-23 EP disclosed
US-6552034-B2 Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-04-22 US disclosed
EP-0880520-B1 BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2003-04-16 EP disclosed
US-6514912-B1 Use of benzo[C]quinolizine derivatives as plant growth regulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-04 US disclosed
US-20010047098-A1 Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-29 US disclosed
US-20010044542-A1 Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors MERCK SERONO SA (CH) 2001-11-22 US disclosed
US-6303622-B1 FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2001-10-16 US disclosed
EP-0999747-A1 USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS Applied Research Systems ARS Holding N.V. (AN) 2000-05-17 EP disclosed
WO-1999005913-A1 USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044542-A1 Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors CYP3A5, CYP51A1, CYP2F1 SRD5A1 8/4885HTR2C 531/4885HTR2B 1556/4885
US-20010047098-A1 Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors CYP3A5, CYP51A1, CYP2F1 SRD5A1 8/4885HTR2C 531/4885HTR2B 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.